European drug regulations need changing to ensure they meet the needs of patients and doctors, argue experts in this week’s BMJ.Licensing of new drugs in Europe is increasingly controlled by the European Medicines Agency (EMEA), yet new drugs have only to show they are equivalent to current treatments rather than show superiority.
